Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

T-cell Infusion Targeting CD19 and CD22 for Refractory/Relapsed Leukemia/Lymphoma Patients With or Without Central Nervous System Involvement

NCT06213636 is registered in ClinicalTrials.gov with Essen Biotech as lead sponsor.

NCT NCT06213636
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06213636 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
T-cell Infusion Targeting CD19 and CD22 for Refractory/Relapsed Leukemia/Lymphoma Patients With or Without Central Nervous System Involvement
Lead sponsor
Essen Biotech
Phase
Phase 1/2
Overall status
Recruiting
Start date
July 10, 2024
Completion date
December 10, 2028
Enrollment
75 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

acute lymphoblastic leukemia, adult b-cell, acute lymphoblastic leukemia, in relapse, central nervous system lymphoma, diffuse large b cell lymphoma, lymphoma, follicular, mcl, non-hodgkin lymphoma, b-cell